Izun Announces Breakthrough in Treatment of Peri-Implantitis affecting Dental Implants

Company Representatives will be available to discuss results at Greater New York Dental Meeting, 30-Nov-2015 – 02-Dec-2015

Izun Oral Care (www.izunoralcare.com) a division of Izun Pharmaceuticals announced positive clinical data in a post-approval trial evaluating PerioPatch in the treatment of peri-implantitis. Peri-implantitis and peri-implant mucositis affect up to 48% of all implants placed. These conditions are associated with pain, abscesses and, if left untreated, can lead to loss of implant.

PerioPatch-Box-izunpharma

A single dose of PerioPatch (6 patches over 3 days) placed on the buccal gingiva was used as sole therapy, with no adjunctive debridement to treat moderate to advanced peri-implantitis lesions. Results were evaluated after only 1 week and demonstrated a rapid reduction in inflammation and bleeding, a reduction of probing depths and a reduction in associated microbial flora (analyzed with DNA probe analysis). The results were both statistically and clinically significant: reduction in inflammation (GI) of 55% (p< 0.0001), reduction in probing depth of greater than 18% with a mean reduction of 1.0mm (p= 0.0003), and a reduction in the load of microbial flora of 40% (p=0. 001).

The currently recommended treatment for peri-implant mucositis, as well as for peri-implantitis, is a combination of anti-inflammatory and anti-bacterial therapy. This trial demonstrates that the PerioPatch topical anti-inflammatory patch is a novel and efficacious breakthrough treatment to assist the clinician in managing this increasingly common and widespread problem.

Dr. Howard Tenenbaum, Professor of Periodontology at the University of Toronto, stated that “This study demonstrates a paradigm shift in the treatment of soft tissue and hard tissue diseases that develop about some implants. Topical anti-inflammatory treatment is a necessary part in the treatment of both peri-implantitis and periodontitis. PerioPatch therapy and the associated rinse (PeriActive) are novel and effective products that will greatly enhance our ability to manage these diseases.”

PerioPatch is a topical oral patch therapy that is applied to the surface of the gingiva and selectively absorbs inflammatory exudates, reducing the signs and symptoms of gingival inflammation. Earlier studies have demonstrated that adjunctive therapy with PerioPatch will also reduce pocket depths and increase clinical attachment levels in moderate-to-severe periodontal disease.